Navigation Links
Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
Date:9/15/2010

DENVER, Sept. 15 /PRNewswire/ -- On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

Dr. Bruner is a past president of the American Society of Bariatric Physicians (ASBP) and will speak to the committee on behalf of the Society's nearly 1,300 members throughout the U.S.  ASBP's physicians know from long experience that obesity can be a lifelong, chronic illness, which ultimately can produce very serious health risks and which can lower the quality of life of those afflicted.  

With recent obesity costs topping $147 billion per year, it is imperative that doctors be better equipped to treat obesity.  Research has shown that medical intervention can assist with weight loss and maintenance, and that weight loss can reverse or retard the development of diabetes, hypertension, sleep apnea and numerous other seriously harmful consequences of obesity.

Patients with obesity have few treatment options. While new obesity drugs are reviewed with great caution due to unexpected adverse reactions of past drugs, there is every reason to be confident that the clinical trials for Lorcaserin have adequately identified the relevant risks. Dr. Bruner, in speaking on behalf of the ASBP, will encourage the FDA advisory committee to consider the demonstrated effectiveness and benefits of this drug as thoroughly as it considers any risks.

About the ASBP

Founded in 1950, the ASBP is the oldest medical association focused on the education and training of medical professionals treating and managing obese patients and associated diseases. The ASBP is a collaborative organization that provides its members practical information and business tools to implement a successful medical bariatric practice. For more information about the ASBP, visit www.asbp.org.


'/>"/>
SOURCE ASBP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
8. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
9. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
10. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):